Naxitamab
| Naxitamab | |
|---|---|
| Term | Naxitamab |
| Short definition | Naxitamab - (pronounced) (nak-SIH-tuh-mab) A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children from 1 year of age and adults with certain types of high-risk neuroblastoma in the bone or bone marrow that have come back or have come back with others no better were treatment. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Naxitamab - (pronounced) (nak-SIH-tuh-mab) A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children from 1 year of age and adults with certain types of high-risk neuroblastoma in the bone or bone marrow that have come back or have come back with others no better were treatment. It is also being studied in the treatment of other types of cancer. Naxitamab attaches to a substance called GD2, which is found on some types of cancer cells. Naxitamab can block GD2 and help the immune system kill cancer cells. It's a type of monoclonal antibody. Also called Danyelza
External links
- Medical encyclopedia article on Naxitamab
- Wikipedia's article - Naxitamab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski